CoChat

Improving Neonatal Screening for Congenital Adrenal Hyperplasia

Speiser, Phyllis W. · 2004 · The Journal of Clinical Endocrinology & Metabolism
Cited by 24

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

In this issue of JCEM, Minutti et al. (1) describe improved positive predictive value of newborn screening for congenital adrenal hyperplasia (CAH) when steroid profiling by liquid chromatograph-tandem mass spectrometry is used as a second-tier test. This disease, present in 1:15,000 to 1:16,000 births, is screened for in most states in the United States and in a number of other countries (2). Considerations in selecting diseases to be screened include population frequency, morbidity and mortality resulting from delayed diagnosis, precision of detection, and efficacy of treatment. Economic costs also weigh into the decision to screen; however, these vary widely depending on the screening protocol, the chosen assay, the selected assay cut-offs, and various efficiencies of scale. Cost-benefit analysis done in the last decade for the Texas program with sample acquisition at birth and at 2 wk of life showed that CAH screening is relatively costly compared with other disease screening programs (3, 4). Despite these data, neonatal CAH screening has been expanding. The rationale includes the fact that at least 50% of cases have not been detected clinically at the time when screening results are reported (5). Earlier detection leads to earlier treatment and avoids severe salt-wasting adrenal crises, thus obviating acute and intensive hospital care associated with even higher costs. Beyond these calculated costs, there are also human costs in failing to identify and treat CAH at an early stage. Until the advent of newborn screening, case reports showed female preponderance, suggesting an as-yet-unknown number of early deaths in affected male infants (6). Infants who survived salt-wasting episodes often suffered permanent neurological damage. Additionally, erroneous gender assignment with attendant long-term psychosexual trauma can be largely avoided through screening. Conversely, mislabeling a healthy child as having a serious inherited disease also carries adverse consequences. Thus, diagnostic precision is of paramount importance. The most widely used and least costly technique is RIA of blood spot 17-hydroxyprogesterone (17OHP); also available are enzyme-linked immunoassay and fluorescent immunoassay. Among the problems encountered with immunoassays are poor antibody specificity in combination with abundant cross-reacting hormones in newborn blood. Lack of assay standardization and noncomparability of filter paper and serum measurements further hamper interpretation of CAH screening results. Furthermore, stress due to prematurity or critical illness generally increases adrenal cortisol and 17OHP secretion in tandem. If only 17OHP is measured, infants may be incorrectly diagnosed as having CAH. Attempts to improve the predictive value of screening programs have included measuring the ratio of 17OHP to cortisol by immunoassay as a second-tier test (7). Stratifying cut-off values by gestational age (8) and/or birthweight (9) is widely used, but none of these strategies has entirely solved the main problem of large numbers of false-positive test results. It is also distressing that immunoassay screening has, in rare cases, failed to identify newborns affected with classic CAH. In view of the fact that a high 17OHP measured by immunoassay does not necessarily predict disease, it is crucial to seek alternative or adjunctive screening methods. Genotyping has been proposed as a second-tier test (10, 11). Employing CYP21A2-specific PCR amplification, a panel of probes or primers for 9–10 mutant alleles can identify about 90–95% of affected haplotypes. Unfortunately, however, this means that without sequencing, about 5–10% of affected alleles could go undetected. There are presently at least 75 known mutant alleles for CYP21A2 (i.e. the active steroid 21-hydroxylase-encoding gene), and the list continues to grow (the Human Gene Mutation Database, http://uwcmml1s.uwcm.ac.uk/uwcm/mg/search/120603.html). Moreover, genotyping, like immunoassay, is not without its own accuracy pitfalls (12). In some PCR-based reports, 15–20% of patients had only one allele characterized (13, 14). The highly complex nature of the chromosome 6p21.3 region with gene and pseudogene encoding active and inactive 21-hydroxylase enzymes, respectively, sometimes in multiple copies, can make genotype interpretation quite difficult. Thus, although genotyping is feasible on a limited scale in commercial laboratories and in research settings, it does not appear ideally suitable at this time for mass screening. Would tandem mass spectrometry be an appropriate choice for a second-tier CAH screening test for perhaps the top 3–5% of the assay results? It is encouraging that measuring 17OHP, androstenedione, and cortisol by liquid chromatography-tandem mass spectrometry in more than 1200 specimens increased the positive predictive value of CAH screening 9-fold over that for 17OHP immunoassay alone, estimated now at about 0.5%. Minutti et al. (1) set the cut-off

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2004-0976

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 24

Metadata

Authors
Speiser, P. W.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2004-08
Volume
89
Issue
8
Pages
3685-3686
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2114586382
Cited by
24
References
7
FWCI
0.55
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.